• Explore /
  • Poster
  • / Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).

Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).

Abstract Poster

Authors

null

Charlotte L. Zuur

Netherlands Cancer Institute (NKI-AVL), Amsterdam, Netherlands

Charlotte L. Zuur , Joris B. W. Elbers , Joris L. Vos , Anne van der Leun , Xiaohang Qiao , Baris Karakullukcu , Michiel W. M. van den Brekel , Bing Tan , Bas Jasperse , Wouter V. Vogel , Laura Smit , Stefan M. Willems , Harm van Tinteren , Abrahim Al-Mamgani , Jasper Nijkamp , Ton N. Schumacher , Christian U. Blank , J. P. De Boer , John B. A. G. Haanen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03003637

Citation

J Clin Oncol 37, 2019 (suppl; abstr 2575)

DOI

10.1200/JCO.2019.37.15_suppl.2575

Abstract #

2575

Poster Bd #

219

Abstract Disclosures

Similar Posters

First Author: Bradley Alexander McGregor

First Author: Milton Jose De Barros E Silva

First Author: Yara L. Verschoor

Poster

2020 ASCO Virtual Scientific Program

Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.

Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.

First Author: Bradley Alexander McGregor